Conference
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.
Abstract
e14637
Background: OVs display oncolytic activity and boost adaptive cell immunity. MG1MA3 is a Maraba virus modified to express tumour antigen MAGE-A3. MG1MA3, both alone and after immune priming with a MAGE-A3 modified adenovirus (AdMA3) may trigger anti-tumour T-cell responses. Methods: N = 41 patients (pts) with MAGE-A3 expressing solid tumours were evaluated in 3 groups (A) Dose escalation of MG1MA3 iv d1+4, q8w (n = 9); …
Authors
Jonker DJ; Hotte SJ; Abdul Razak AR; Renouf DJ; Lichty B; Bell JC; Powers J; Breitbach CJ; Stojdl DF; Stephenson KB
Volume
35
Pagination
pp. e14637-e14637
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2017
DOI
10.1200/jco.2017.35.15_suppl.e14637
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X